Product image of Natriumjodid (131i) Curium (Sodium Iodide (131i)) supplied by GNH India

Natriumjodid (131i) Curium

Active Ingredient:
Sodium Iodide (131i)
Origin:
EU

Natriumjodid (131i) Curium (Sodium Iodide (131i))

Sodium Iodide I-131, the active ingredient in Natriumjodid (131i) Curium, is a radioactive iodine presented as an oral radiopharmaceutical solution for oral use. It is employed in the treatment of thyroid cancer, management of hyperthyroidism, and in diagnostic imaging of thyroid tissue.

GNH India supplies Natriumjodid (131i) Curium as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, adhering to EU regulatory standards.

Manufacturer / TM Owner

Curium Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Natriumjodid (131i) Curium, a radioactive iodine, is used in conditions affecting thyroid function.

  • Thyroid cancer ablation: eliminates residual thyroid tissue after surgery to reduce recurrence risk.
  • Hyperthyroidism (e.g., Graves disease): reduces overactive thyroid hormone production by destroying follicular cells.
  • Diagnostic imaging of thyroid tissue: enables visualization of functional thyroid tissue and metastatic disease through gamma emission imaging.

How It Works

  • After oral administration, sodium iodide I-131 is absorbed and selectively taken up by thyroid follicular cells via the sodium‑iodide symporter. The beta particles emitted cause localized cytotoxicity, destroying thyroid tissue, while the accompanying gamma photons permit external imaging of thyroid distribution and metastatic sites. The selective uptake limits systemic exposure, making it effective for both therapeutic ablation and diagnostic scintigraphy.

Side Effects

Sodium Iodide I-131 may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Nausea: mild gastrointestinal upset occurring shortly after dosing.
  • Dry mouth: reduced salivary flow due to radiation of salivary glands.
  • Taste alteration: transient metallic or bitter taste sensation.
  • Sialadenitis: inflammation of salivary glands causing discomfort.

Serious or Rare Side Effects

  • Bone marrow suppression: decreased blood cell counts leading to infection risk.
  • Severe hypothyroidism: excessive loss of thyroid function requiring hormone replacement.
  • Pulmonary fibrosis: rare lung tissue scarring after high cumulative doses.
  • Allergic reaction: rash, itching, or anaphylaxis in sensitive individuals.

Precautions & Warnings

Prior to prescribing Sodium Iodide I-131, several safety considerations should be evaluated.

  • Pregnancy: avoid use unless benefits outweigh potential fetal radiation exposure.
  • Breastfeeding: discontinue nursing as the drug can be secreted in milk.
  • Renal function: assess kidney performance because excretion is renal.
  • Thyroid status: confirm indication and baseline thyroid hormone levels.
  • Radiation safety: implement protective measures for patients and staff to limit exposure.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Sodium Iodide I-131 can interact with other medications that affect thyroid function or radiation response.

Major Interactions (Avoid)

  • Antithyroid drugs (e.g., methimazole): may block iodine uptake, reducing efficacy.
  • Thyroid hormone replacement therapy: can diminish therapeutic effect if dosing is not adjusted.
  • Lithium: interferes with thyroid iodine handling, potentially altering treatment outcome.

Moderate Interactions (Monitor Closely)

  • Amiodarone: high iodine content may affect radioiodine distribution.
  • Potassium iodide: competitive inhibition of iodine uptake.
  • Chemotherapy agents: additive risk of bone marrow suppression.

Frequently Asked Questions

Natriumjodid (131i) Curium, containing Sodium Iodide I-131, is used to ablate residual thyroid tissue after thyroid cancer surgery, to treat hyperthyroidism by reducing overactive thyroid cells, and to provide diagnostic imaging of thyroid tissue and metastatic disease through its gamma emissions.

After oral intake, the compound is taken up by thyroid follicular cells via the sodium‑iodide symporter. The beta radiation emitted destroys thyroid cells locally, while the gamma radiation allows clinicians to image thyroid distribution and any metastatic sites.

The exact activity prescribed is determined by the treating physician based on the specific indication, patient weight, thyroid size, and prior treatments. Dosing is individualized and should follow a qualified medical professional’s recommendation.

Use during pregnancy is generally avoided because the radioactive iodine can expose the fetus to radiation. Breastfeeding should be discontinued, as the drug can be secreted in breast milk and pose a risk to the infant.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with surgical removal, I-131 offers a non‑invasive option that can target residual tissue. Unlike antithyroid drugs, it provides a definitive reduction of thyroid activity. It is also unique in allowing simultaneous therapeutic and diagnostic (scintigraphic) capabilities.

Store at ambient temperature, preferably below 25 °C. Keep the product in its original sealed container, protect it from moisture and direct light, and follow any specific handling instructions provided with the shipment.

The medication is administered orally as a single dose in a liquid or capsule form, under the supervision of a qualified healthcare professional. Patients are usually instructed to fast briefly before and after dosing to optimize thyroid uptake.

Serious risks include bone marrow suppression, which can lower blood cell counts; severe hypothyroidism requiring lifelong hormone replacement; pulmonary fibrosis after high cumulative doses; and rare allergic reactions that may be life‑threatening.

Patients who are pregnant, actively breastfeeding, have severe renal impairment, or have uncontrolled thyroid disorders not suitable for radioiodine therapy should not receive this product. Contra‑indications are determined by the prescribing physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sodium Iodide (131i)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT